646P Iparomlimab and tuvonralimab (QL1706) plus chemotherapy and bevacizumab for epidermal growth factor receptor inhibitor (EGFRi)-resistant, EGFR-mutant, advanced non-small cell lung cancer (NSCLC): Updated results from Cohort 5 in the DUBHE-L-201 study
W.F. Fang(Sun Yat-sen University), L. Zhang(Sun Yat-sen University), G. Chen(Harbin Medical University), Y. Zhang(Sun Yat-sen University), Yuanyuan Huang(The Affiliated Yongchuan Hospital of Chongqing Medical University), Tao Wu(Central South University), Haiyan Li(Shihezi University), Li‐Mei Chen(Sun Yat-sen University), Hongyu Zhao(Sun Yat-sen University), Yadong Yang(Sun Yat-sen University), Na Zhou(Qingdao University), Tianlun Zhou(Fox Chase Cancer Center), Yuguang Zhao(Jilin University), Xiaoxu Kang(Shanghai Medical Information Center)
Cited by 1
Related Papers
DNA methylation on N6-adenine in mammalian embryonic stem cells
|Nature|2016|672
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
|Annals of Oncology|2015|467
Avian Influenza (H5N1) Viruses Isolated from Humans in Asia in 2004 Exhibit Increased Virulence in Mammals
|Journal of Virology|2005|460
N-methyladenine DNA Modification in Glioblastoma
|Cell|2018|340
Transcriptional inhibiton of Hoxd4 expression by miRNA-10a in human breast cancer cells
|BMC Molecular Biology|2009|193